Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.
- Market Cap ₹ 7,961 Cr.
- Current Price ₹ 1,845
- High / Low ₹ 2,408 / 1,502
- Stock P/E 18.4
- Book Value ₹ 441
- Dividend Yield 0.33 %
- ROCE 25.1 %
- ROE 22.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|
829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,505 | |
567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,808 | |
Operating Profit | 261 | 509 | 689 | 481 | 711 | 698 |
OPM % | 32% | 33% | 31% | 25% | 28% | 28% |
2 | 4 | 8 | 7 | 16 | 22 | |
Interest | 29 | 44 | 66 | 73 | 53 | 62 |
Depreciation | 74 | 86 | 109 | 124 | 133 | 141 |
Profit before tax | 161 | 383 | 522 | 291 | 541 | 517 |
Tax % | 37% | 34% | 32% | 33% | 34% | |
101 | 253 | 353 | 196 | 358 | 433 | |
EPS in Rs | 24.48 | 60.84 | 85.03 | 47.14 | 82.91 | 100.98 |
Dividend Payout % | 0% | 0% | 6% | 11% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 18% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
TTM: | 73% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 25% |
Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 42 | 42 | 42 | 42 | 43 |
Reserves | 432 | 684 | 1,028 | 1,213 | 1,861 |
753 | 993 | 879 | 964 | 593 | |
222 | 405 | 484 | 576 | 655 | |
Total Liabilities | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 |
1,102 | 1,068 | 1,804 | 1,767 | 2,238 | |
CWIP | 126 | 589 | 158 | 483 | 64 |
Investments | 0 | 0 | 21 | 21 | 98 |
221 | 467 | 450 | 524 | 752 | |
Total Assets | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
229 | 284 | 626 | 398 | 441 | |
-197 | -455 | -437 | -401 | -262 | |
-32 | 195 | -200 | -8 | -164 | |
Net Cash Flow | 1 | 24 | -11 | -11 | 15 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 52 | 60 | 28 | 34 | 33 |
Inventory Days | 51 | 74 | 69 | 90 | 105 |
Days Payable | 69 | 42 | 36 | 63 | 50 |
Cash Conversion Cycle | 34 | 92 | 61 | 61 | 88 |
Working Capital Days | -92 | -26 | -41 | -54 | 26 |
ROCE % | 29% | 32% | 17% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 Aug - One-on-one investor meetings in Mumbai on 21 Aug 2025 with four institutional investors.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 Aug - The Company is having One on One Meeting through V.C.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Aug - Epigral Limited submits Intimation of Participation in Conference "Emkay Confluence - India Ascending: The Next Leap" on 12th August, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Aug - Epigral schedules one-on-one virtual meeting with EverFlow Partners on 8 Aug 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
6 Aug - Q1 FY26: 6% revenue decline, 27% EBITDA margin, ongoing capacity expansions, new plant commissioned, future growth expected.
Annual reports
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024Transcript PPT
-
Apr 2024TranscriptNotesPPT
-
Apr 2024Transcript PPT REC
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]